Menke Marcel N, Ebneter Andreas, Zinkernagel Martin S, Wolf Sebastian
Department of Ophthalmology, Cantonal Hospital Aarau, Aarau, Switzerland; Department of Ophthalmology, Inselspital, University Hospital of Bern and University of Bern, Bern, Switzerland.
Department of Ophthalmology, Inselspital, University Hospital of Bern and University of Bern, Bern, Switzerland.
J Ophthalmol. 2016;2016:9875741. doi: 10.1155/2016/9875741. Epub 2016 Dec 1.
. Ranibizumab is approved for treatment of macular edema in eyes with retinal vein occlusion (RVO). Some eyes show low-response to treatment with regard to visual acuity gain (VA) and OCT central retinal thickness (CRT) reduction. The goal of this study was to quantify the percentage of low-responders. . Treatment of naïve eyes with macular edema secondary to RVO was included and monthly VA and CRT were analyzed. Four weeks after the loading phase, and at the end of the study, eyes were grouped into low- and good responders based on predefined criteria. The responder and low-responder groups were then compared at various time points. . Forty-three eyes were included. Regarding VA, 27.9% were low-responders after the loading phase and 30.2% at the end of the study. For CRT, 34.9% were low-responders after the loading phase versus 27.9% at the end of the study. 75% of patients that were VA low-responders and 73.3% of CRT low-responders after loading phase remained low-responders at the end of the study. . Approximately 30% of patients showed low response to ranibizumab after the loading phase and after 1 year of treatment. Two-thirds of patients that were low-responders after the loading phase remained low-responders after 1 year.
雷珠单抗被批准用于治疗视网膜静脉阻塞（RVO）引起的黄斑水肿。一些眼睛在视力提高（VA）和光学相干断层扫描（OCT）测量的中心视网膜厚度（CRT）降低方面对治疗反应不佳。本研究的目的是量化反应不佳者的比例。纳入了初治的RVO继发性黄斑水肿患者的治疗，并分析每月的VA和CRT。在负荷期后四周以及研究结束时，根据预先定义的标准将眼睛分为反应不佳者和反应良好者两组。然后在不同时间点比较反应者组和反应不佳者组。纳入了43只眼睛。关于VA，负荷期后27.9%为反应不佳者，研究结束时为30.2%。对于CRT，负荷期后34.9%为反应不佳者，研究结束时为27.9%。负荷期后VA反应不佳的患者中有75%以及CRT反应不佳的患者中有73.3%在研究结束时仍为反应不佳者。负荷期后以及治疗1年后，约30%的患者对雷珠单抗反应不佳。负荷期后反应不佳的患者中有三分之二在1年后仍为反应不佳者。
